2-[(6-Chloro-5-fluoro-2-benzothiazolyl)amino]-N-phenylacetamide | 634909-28-7

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 2-[(6-Chloro-5-fluoro-2-benzothiazolyl)amino]-N-phenylacetamide
• 英文别名: 2-[(6-chloro-5-fluoro-1,3-benzothiazol-2-yl)amino]-N-phenylacetamide
• CAS: 634909-28-7
• 化学式: C₁₅H₁₁ClFN₃OS
• 分子量: 335.8
• InChiKey: PCJGPEUZALDVMK-UHFFFAOYSA-N

物化性质

• 密度：
  1.530±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  22
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  82.3
• 氢给体数：
  2
• 氢受体数：
  5

文献信息

• 6-O-SUBSTITUTED BENZOXAZOLE AND BENZOTHIAZOLE COMPOUNDS AND METHODS OF INHIBITING CSF-1R SIGNALING
  申请人：Sutton C James

  公开号：US20080045528A1

  公开（公告）日：2008-02-21

  Benzoxazole and benzothiazole compounds and the stereoisomers, tautomers, solvates, oxides, esters, and prodrugs thereof and pharmaceutically acceptable salts thereof are disclosed. Compositions of the compounds, either alone or in combination with at least one additional therapeutic agent, with a pharmaceutically acceptable carrier, and uses of the compounds, either alone or in combination with at least one additional therapeutic agent are also disclosed. The embodiments are useful for inhibiting cellular proliferation, inhibiting the growth and/or metathesis of tumors, treating or preventing cancer, treating or preventing degenerating bone diseases such as rheumatoid arthritis, and/or inhibiting molecules such as CSF-1R.

  苯并噁唑和苯并噻唑化合物及其立体异构体、互变异构体、溶剂合物、氧化物、酯类和前药以及其药学上可接受的盐已被披露。所述化合物的组合物，无论是单独使用还是与至少一种额外治疗剂组合，并与药学上可接受的载体一起使用的用途也已被披露。这些实施例可用于抑制细胞增殖，抑制肿瘤的生长和/或交换反应，治疗或预防癌症，治疗或预防类风湿性关节炎等退行性骨病，以及/或抑制CSF-1R等分子。
• 6-O-Substituted Benzoxazole and Benzothiazole Compounds and Methods of Inhibiting CSF-1R Signaling
  申请人：Sutton James C.

  公开号：US20120225861A1

  公开（公告）日：2012-09-06

  Benzoxazole and benzothiazole compounds and the stereoisomers, tautomers, solvates, oxides, esters, and prodrugs thereof and pharmaceutically acceptable salts thereof are disclosed. Compositions of the compounds, either alone or in combination with at least one additional therapeutic agent, with a pharmaceutically acceptable carrier, and uses of the compounds, either alone or in combination with at least one additional therapeutic agent are also disclosed. The embodiments are useful for inhibiting cellular proliferation, inhibiting the growth and/or metathesis of tumors, treating or preventing cancer, treating or preventing degenerating bone diseases such as rheumatoid arthritis, and/or inhibiting molecules such as CSF-1R.

  公开了苯并噻唑化合物和苯并噻唑类化合物的立体异构体、互变异构体、溶剂化物、氧化物、酯和前药及其药学上可接受的盐。还公开了这些化合物的组合物，其可以与至少一种额外的治疗剂一起使用，并与药学上可接受的载体结合使用。这些实施例对于抑制细胞增殖、抑制肿瘤的生长和/或代谢、治疗或预防癌症、治疗或预防退化性骨疾病如类风湿性关节炎以及/或抑制CSF-1R等分子具有用途。
• 6-O-substituted benzoxazole and benzothiazole compounds and methods of inhibiting CSF-1R signaling
  申请人：Sutton James C.

  公开号：US20100280006A1

  公开（公告）日：2010-11-04

  Benzoxazole and benzothiazole compounds and the stereoisomers, tautomers, solvates, oxides, esters, and prodrugs thereof and pharmaceutically acceptable salts thereof are disclosed. Compositions of the compounds, either alone or in combination with at least one additional therapeutic agent, with a pharmaceutically acceptable carrier, and uses of the compounds, either alone or in combination with at least one additional therapeutic agent are also disclosed. The embodiments are useful for inhibiting cellular proliferation, inhibiting the growth and/or metathesis of tumors, treating or preventing cancer, treating or preventing degenerating bone diseases such as rheumatoid arthritis, and/or inhibiting molecules such as CSF-1R.

  本文披露了苯并噁唑和苯并噻唑化合物及其立体异构体、互变异构体、溶剂化物、氧化物、酯类和前药，以及其药学上可接受的盐。本文还披露了这些化合物的组合物，可以单独使用或与至少一种其他治疗剂联合使用，并与药学上可接受的载体一起使用，以及这些化合物的用途，可以单独使用或与至少一种其他治疗剂联合使用。这些实施例可用于抑制细胞增殖，抑制肿瘤的生长和/或代谢，治疗或预防癌症，治疗或预防退化性骨病，如类风湿性关节炎，和/或抑制分子，如CSF-1R。
• US7553854B2
  申请人：——

  公开号：US7553854B2

  公开（公告）日：2009-06-30
• US8173689B2
  申请人：——

  公开号：US8173689B2

  公开（公告）日：2012-05-08